Initiate or optimize guideline-directed medical therapy (GDMT) and address modifiable drivers of disease progression.

• Initiate or titrate GDMT consistent with HF phenotype and comorbidities
• Refer to cardiology when diagnostic uncertainty, disease progression, or therapy escalation is present
• Identify and treat contributors to HF progression, including hypertension, CKD, sleep apnea, obesity, inactivity, and substance exposure